Pilman

An Editorial Journal by Tapan Ray | Pharmaceuticals & Healthcare

Perspectives on Pharma, Healthcare & Policy

A dedicated space bringing together years of writing, speeches, presentations, and references around pharmaceuticals, healthcare, policy, and industry evolution.

Latest articles

From Voluntary Promises to Enforceable Accountability: Can India Finally Make Ethical Pharma Marketing Work?

F

Executive Summary: India’s pharmaceutical marketing regulation is at an important turning point. The Uniform Code of Pharmaceutical Marketing Practices (UCPMP implementation), introduced in 2015 as a voluntary initiative, was intended to promote ethical relationships between pharmaceutical companies and healthcare professionals. However, voluntary self-regulation did not deliver adequate accountability. The Government acknowledged this limitation in its 2017–18 Annual Report and...

Drug Innovation and Stronger IPR: How Will the Common Patient Really Benefit?

D

Executive Summary • India’s ambition to strengthen intellectual property rights (IPR) while encouraging drug innovation raises an important question: how can stronger patent protection help create new medicines without putting their benefits beyond the reach of ordinary patients? • India wants to move beyond its traditional strength in generic medicines and become a stronger center for pharmaceutical innovation. This is an important ambition. Developing new medicines can address unmet...

Saving Lives Today, Enabling Cures Tomorrow: Can India Get Medicine Affordability Right?

S

Executive Summary: How can India make life-saving medicines affordable today without compromising its ability to develop the cures of tomorrow? This is one of the most consequential questions facing Indian healthcare and the pharmaceutical industry. Recent developments have brought the issue into sharp focus. On 17 October 2026, the Government announced trade-margin rationalization for 137 non-scheduled anti-cancer medicines. On 28 October, the National Pharmaceutical Pricing Authority (NPPA)...

Beyond the Next Brand: When Growth Becomes the Brand Launch Trap

B

Why the quality of brand-launch decisions matters more than the number of products added to a portfolio Executive Summary: In India’s predominantly branded-generic pharmaceutical market, an effective pharmaceutical brand launch strategy requires more than introducing another product to pursue growth. A familiar molecule, an established therapeutic category and a sizeable market may make a new brand commercially attractive, but a larger portfolio does not automatically create a stronger...

Indian Pharma’s Growth Challenge: Can Every Brand Create Meaningful Patient Value?

I

Why sustainable business growth should begin with unmet patient needs—not simply another product launch. Executive Summary: Patient value in Indian pharma must become a measurable driver of sustainable business growth—not merely a marketing aspiration. Growth is essential for every pharmaceutical company. It sustains profitability, rewards investment and funds future innovation. But launching more products and...

Climate Change and Patient Safety: Is Indian Pharma’s Quality System Ready for a New Reality?

C

Executive Summary: Climate change is becoming a new stress test for pharmaceutical quality systems. Extreme heat, flooding, power failures and transport disruption can threaten the storage, distribution and availability of medicines. For Indian pharma, the challenge is to move beyond routine compliance towards climate-resilient systems that anticipate risks, assess deviations scientifically and protect patients throughout the supply chain. Quality Beyond the Factory Gate: A medicine may leave a...

The Invisible Economics of Indian Pharma Growth: What Is Boosting It—and What Is Quietly Holding It Back?

T

Indian pharmaceutical growth is generally measured through sales, exports, new launches, acquisitions, margins and investments. – But some of the forces shaping that growth do not appear clearly in these numbers. They sit underneath them. – The rising cost of being compliant. The changing economics of marketing. The productivity of field forces. The ability to use data responsibly. The cost of demonstrating product value. The capacity to convert regulatory requirements into...

One Extreme Example, One Big Question: Should India Put Every Medicine Under Price Control?

O

The Supreme Court’s intervention on drug pricing raises a legitimate concern. But it also opens a much larger question: how should India balance the affordability of medicines today with the investment needed to discover medicines for patients tomorrow? On September 22, 2026, the Supreme Court expressed strong concern after being informed that a cancer medicine supplied to a retailer at about ₹2,700 carried an MRP of ₹27,000—a ten-fold difference. The Bench described the situation in...

How Can a Pharmaceutical Company Prove That Its Strategic Decisions Made Healthcare Better—Measurably?

H

From strategic intent to measurable patient impact: a practical roadmap for Indian pharma Pharmaceutical companies routinely describe their strategies as patient-centric, evidence-based and outcome-oriented. But there is a harder question that receives far less attention: What evidence can a company produce to show that a major strategic decision actually improved something that matters to patients? This question is becoming increasingly relevant in India. Healthcare delivery is becoming more...

Indian Pharma Has a Leadership Challenge: Can Patient Value, Employee Fulfilment and Business Growth Become the Same Goal?

I

India’s pharmaceutical industry is entering another important phase of growth. The ambition is clear. The industry is being encouraged to invest more in clinical research and R&D, move towards higher-value products, strengthen manufacturing capabilities and become more competitive globally. At the same time, the regulatory environment is evolving towards greater risk-based and proportionate oversight without compromising quality, safety and efficacy. At iPHEX 2026, CDSCO outlined this...

Pilman An Editorial Journal by Tapan Ray | Pharmaceuticals & Healthcare

Tapan Ray

Tapan Ray

Tapan Ray is a veteran pharmaceutical executive, healthcare strategist, and influential thought leader with decades of leadership experience in the healthcare industry. Through this blog, he explores the forces transforming medicine from pharmaceutical innovation and digital transformation to healthcare policy and patient-centric business models.

Combining extensive industry experience with sharp analytical insight, Tapan challenges conventional thinking and offers fresh perspectives on how bold ideas can drive meaningful change in healthcare and improve lives.

Follow Me